Featured Articles

Clonazepam disintegrating tablets |...

Clonazepam orally disintegrating tablets (0.125 mg, 0.25 mg, 0.5 mg, 1 mg, and 2 mg) have been approved, alone or as a...

Teva Announces Tentative Approval o...

JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administra...

Acusphere Licenses Hydrophobic Drug...

Cephalon to use Technology for Oncology Applications

Acute oral and ocular changes in a ...

[ILLUSTRATION OMITTED]

통풍을 위한 약 그리고 규...

지난 몇년간에서 이라고 칭한 유명한 조건을 위한 새로운 처리는 발견되지 않았다. 질병의...

FIND A DRUG

Pharmacy Locator

ZIP Distance

Use this tool to find
pharmacies in your area

FDA News Release

Consumer Updates

Axcan Pharma Inc. Reaches Agreement to Purchase Jouveinal's Products ...

Back

MONTREAL--(BUSINESS WIRE)--Sept. 3, 1997--(ME,TSE:AXP.) Axcan Pharma Inc. announces that it completed a transaction with Parke-Davis, a division of Warner-Lambert Company, for the acquisition by Axcan of all gastroenterology products previously marketed by Jouveinal in Canada.